Jin Chengjuan, Xue Yingfeng, Li Yingwei, Bu Hualei, Yu Hongfeng, Zhang Tao, Zhang Zhiwei, Yan Shi, Lu Nan, Kong Beihua
Int J Gynecol Cancer. 2018 Jan;28(1):51-58. doi: 10.1097/IGC.0000000000001141.
High-grade serous ovarian cancer (HGSOC) accounts for approximately 70% deaths in ovarian cancer. The overall survival (OS) of HGSOC is poor and still remains a clinical challenge. High-grade serous ovarian cancer can be divided into 4 molecular subtypes. The prognosis of different molecular subtypes is still unclear. We aimed to investigate the prognostic values of immunohistochemistry-based different molecular subtypes in patients with HGSOC.
We analyzed the protein expression of representative biomarkers (CXCL11, HMGA2, and MUC16) of 3 different molecular subtypes in 110 formalin-fixed, paraffin-embedded HGSOC by tissue microarrays.
High CXCL11 expression predicted worse OS, not disease-free survival (DFS; P = 0.028 for OS, P = 0.191 for DFS). High HMGA2 expression predicted worse OS and DFS (P = 0.037 for OS, P = 0.021 for DFS). MUC16 expression was not associated with OS or DFS (P = 0.919 for OS, P = 0.517 for DFS). Multivariate regression analysis showed that CXCL11 combined with HMGA2 signature was an independent predictor for OS and DFS in patients with HGSOC.
CXCL11 combined with HMGA2 signature was a clinically applicable prognostic model that could precisely predict an HGSOC patient's OS and tumor recurrence. This model could serve as an important tool for risk assessment of HGSOC prognosis.
高级别浆液性卵巢癌（HGSOC）约占卵巢癌死亡病例的70%。HGSOC的总生存期（OS）较差，仍是一项临床挑战。高级别浆液性卵巢癌可分为4种分子亚型。不同分子亚型的预后仍不明确。我们旨在研究基于免疫组织化学的不同分子亚型对HGSOC患者的预后价值。
我们通过组织芯片分析了110例福尔马林固定、石蜡包埋的HGSOC中3种不同分子亚型的代表性生物标志物（CXCL11、HMGA2和MUC16）的蛋白表达。
CXCL11高表达预示着较差的总生存期，但无病生存期（DFS）无差异（总生存期P = 0.028，无病生存期P = 0.191）。HMGA2高表达预示着较差的总生存期和无病生存期（总生存期P = 0.037，无病生存期P = 0.021）。MUC16表达与总生存期或无病生存期无关（总生存期P = 0.919，无病生存期P = 0.517）。多因素回归分析显示，CXCL11与HMGA2特征相结合是HGSOC患者总生存期和无病生存期的独立预测因素。
CXCL11与HMGA2特征相结合是一种临床适用的预后模型，可精确预测HGSOC患者的总生存期和肿瘤复发。该模型可作为HGSOC预后风险评估的重要工具。
